Discover Study, First Analysis Specific for Secondary Progressive Multiple Sclerosis Burden and Cost in Spain: Interim Analysis Results

Author(s)

Oreja-Guevara C¹, Río Izquierdo J², Ara Callizo JR³, Hernández-Pérez MA⁴, Gracia Gil J⁵, Pilo de la Fuente B⁶, Ramió-Torrentà L⁷, Alonso Torres AM⁸, Eichau S⁹, Martínez Yélamos S¹⁰, Casanova Estruch B¹¹, Gascón Giménez F¹², Aguado Valcárcel ML¹³, Martínez Ginés ML¹⁴, López de Silanes C¹⁵, El Berdei Montero Y¹⁶, López Real AM¹⁷, Martínez Rodríguez JE¹⁸, González Quintanilla V¹⁹, Labiano Fontcuberta A²⁰, Costa-Frossard França L²¹, Garcés Redondo M²², García Merino JA²³, Castellanos Pinedo F²⁴, Meca-Lallana V²⁵, Muñoz Fernández C²⁶, Castillo Triviño T²⁷, Rodríguez A²⁸, Peña Martínez J²⁹, Prieto González JM³⁰, Solar Sánchez DM³¹, Agüera Morales E³², Molina MI³³, Herrera Varo N³⁴, Aguirre Vazquez M³⁵, Meca-Lallana J³⁶
¹Hospital Universitario Clínico San Carlos, Madrid, Spain, ²CEMCAT, Hospital Universitario Vall d’Hebron, Barcelona, Spain, ³Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁴Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, ⁵Complejo Hospitalario Universitario de Albacete, Albacete, Spain, ⁶Hospital Universitario de Getafe, Madrid, Spain, ⁷Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain, ⁸Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁹Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain, ¹²Hospital Clínico de Valencia, Valencia, Spain, ¹³Hospital Álvaro Cunqueiro, Vigo, Spain, ¹⁴Hospital Gregorio Marañón, Madrid, Spain, ¹⁵Hospital Universitario de Torrejón, Madrid, Spain, ¹⁶Hospital Universitario de Salamanca, Salamanca, Spain, ¹⁷Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ¹⁸Hospital del Mar, Barcelona, Spain, ¹⁹Hospital Universitario Marqués de Valdecilla, Cantabria, Spain, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Hospital Universitario Ramón y Cajal, Madrid, Spain, ²²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²³Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁴Hospital Virgen del Puerto Plasencia, Cáceres, Spain, ²⁵Hospital Universitario La Princesa, Madrid, Spain, ²⁶Hospital Universitario Torrecárdenas, Almería, Spain, ²⁷Hospital Universitario Donostia, Guipúzcoa, Spain, ²⁸Cruces University Hospital, Basque Country, Baracaldo, Spain, ²⁹Hospital Universitario San Agustín, Asturias, Spain, ³⁰Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ³¹Hospital Universitario de Cabueñes, Gijón, Spain, ³²Hospital Universitario Reina Sofia, Córdoba, Spain, ³³Hospital Virgen de la Salud, Toledo, Spain, ³⁴Hospital Universitario de Burgos, Burgos, Spain, ³⁵Novartis Farmacéutica S.A., Barcelona, Spain, ³⁶Hospital Clínico Universitario Virgen de Arrixaca, Murcia, Spain

OBJECTIVES :

Secondary Progressive Multiple Sclerosis (SPMS) is a form of multiple sclerosis (MS) associated with an important economic burden. Given the limited published data, the main objective of the DISCOVER study was to estimate the economic impact of SPMS in Spain.

METHODS :

DISCOVER is an observational, non-interventional, cross-sectional, retrospective and multicentre study. Patients ≥18 years with SPMS treated and monitored under routine clinical practice in 34 Spanish public hospitals were included. Total sample of 299 patients. All data collected in one single visit. Primary endpoint is total annual cost per patient, including direct healthcare, direct non-healthcare costs and indirect costs. First data from interim results are presented.

RESULTS :

99 evaluable patients: 62.6% females; mean (SD) age of 53.1 (9.3) years; mean (SD) EDSS at the study visit of 5.9 (0.8). Mean (SD) time since first diagnosis of MS was 17.5 (8.9) years, and since progression to SPMS, 5.2 (4.3) years. Visits to specialists (% patients) in the previous year included: neurologist (100.0%), primary care (65.7%), neurology nursing (60.6%) and psychologist (26.3%). Regarding supportive care, 10 (10.1%) and 49 (49.5%) patients assisted to a day care centre and rehabilitation, with a mean (SD) of 11.0 (37.9) and 54.1 (73.7) visits in the previous year, respectively.

Total mean (SD) annual cost of SPMS per patient was 24,724€ (14,344), comprising mean (SD) direct healthcare costs of 11,846€ (9,417), mean (SD) direct non-healthcare costs of 5,965€ (9,528) and mean (SD) indirect costs of 6,914€ (4,459). Direct healthcare costs were higher for females, non-active workers due to early retirement, inability or unemployment, patients with EDSS score at visit ≥6 and patients with SPMS diagnosis ≥ 10 years.

CONCLUSIONS

An economic burden of 24,724€ per patient/year was attributable to SPMS in Spain from the societal perspective, with direct healthcare costs representing 48% of the total costs.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)

Code

PND22

Topic

Economic Evaluation

Disease

Neurological Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation